The balance of co-stimulatory and inhibitory immunological checkpoints is closely linked to immune response modulation, which is employed by many cancers to escape immune system attack. Currently, drugs and therapies designed to target immune checkpoints, such as anti-PD-1 and anti-PD-L1 antibody medications, are demonstrating remarkable efficacy in fighting cancers. However, they face other hurdles, such as dissatisfied overall response rates for low mutational load and side consequences. To overcome these difficulties and accelerate cancer therapy development, a thorough knowledge of immunological checkpoints is extremely important.
Fig.1 The expression profile of immune checkpoints.1
To overcome these difficulties and accelerate cancer therapy development, Creative Biolabs provides a cost-effective immune checkpoint reporter assay service. As a result of their adaptability and efficiency, reporter gene assays are crucial tools in the study of pharmacological compounds. In our immune checkpoint reporter assay, we utilize the reporter gene reaction in response to evaluate antibody drug efficiency. Powered by experts with extensive expertise, Creative Biolabs provides a complete package encompassing everything from design to data qualification, all with the goal of meeting global customers' diverse demands.
Fig.2 Workflow of our immune checkpoint reporter assay.
Our Advantages
We have established cell engineering platforms and successfully produced various stable and functional cell lines, which are often picked for their projects by our global customers. Furthermore, our well-established bioassay platform has been applied for tens of thousands of experiments and is now highly mature.
Our research team consists of many experts with experience and expertise. Moreover, our research team keeps up with the pace of development and always equips themselves with the most advanced knowledge. Together with our competent research team, we have more confidence in presenting desirable outcomes for global customers.
We provide one-stop customized services encompassing everything from design to data qualification to satisfy our global customers' diverse needs.
| Assays | Targets |
| Immune Checkpoint Activation Assay | OX-40; GITR; CD-40; 4-1BB |
| Immune Checkpoint Inhibition Assay | PD-1; TIGIT; PD-L1; LAG3; CTLA-4; TIM-3 |
| Dual Target Bioassay | PD-1/TIGIT; PD-1/4-1BB; PD-1/LAG3; PD-1/CTLA-4 |
| Cytokine and Cellular Signaling-related Bioassay | VEGF-VEGFR2; TIE2-ANG2; IL-1β; IL-33; IL-1α; IL-36 |
| Myeloid cell checkpoint Bioassay | CD47-SIRPα |
As a novel immunological checkpoint, TIGIT has attracted interest as a possible target for immunotherapy in the fight against cancer. In this study, CHO-CD112-CD3 scFv and Jurkat-NFAT-TIGIT were designed as reporter gene cell lines. The target cell, CHO-CD112-CD3 scFv, exhibits a stable expression of anti-CD3 scFv and CD112. Additionally, Jurkat-NFAT-TIGIT maintains stable expression of the NFAT response element-controlled luciferase gene and TIGIT. Studies of validation and optimization have established the superiority of this assay with respect to specificity, accuracy, linearity, and precision.
Fig.3 Reporter gene assay conditions optimization.2
Creative Biolabs strives to improve our technologies and services for the purpose of aiding in drug development. In this field, whether you're looking to target co-inhibitory, co-stimulatory, or a mix of receptors on immunological checkpoints, we have the resources to fulfill your demands. For more details about our immune checkpoint assay, please don't hesitate to contact us.
References
For Research Use Only.
